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Summary Intravenous amiodarone (AMD) induces multiple antiarrhythmic effects
via blocking of Na+, Ca2+, and IKr channels, and  receptors. A patient on chronic dial-
ysis was administered AMD for nonsustained ventricular tachycardia after successful
cardiopulmonary resuscitation. QT prolongation occurred 5 h after AMD adminis-
tration. AMD was withdrawn at 24 h because of prolonged QTc interval (716ms),
which persisted for a further 48 h (661ms). Ventricular premature contraction (VPC)
was signiﬁcantly decreased at 7 h; however, VPC increased again after discontin-
uing AMD. Depolarization changes induced by the Na+-channel blocking action of
AMD were analyzed. There was increasing ﬁltered QRS-duration and duration of
low-amplitude signals at voltage <40V, and decreasing root-mean-square voltage
of signals in the last 40ms of ventricular late potentials (LPs) within 7 h. However
after stopping AMD, LPs were reversed. The blood concentration of AMD reached
the effective level within 10min but decreased immediately to an ineffective level.
Onset and disappearance of the VPC-inhibiting effect corresponded to the depressive
effect on depolarization but not with the increase in the prolonged repolarization
effect and blood concentration. Even if the QT interval is sufﬁciently prolonged, the
Na+-channel blocking action is required for AMD to induce the antiarrhythmic effect.
© 2009 Japanese College of
reserved.
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6nalysis of late potentials by intravenous amiodaro
ntroduction
he control of refractory ventricular ﬁbrillation and
achycardia (VT/VF) during cardiopulmonary resus-
itation (CPR) is an issue of utmost importance. The
uperior deﬁbrillation effect of intravenous admin-
stration of amiodarone compared with lidocaine
as already been reported [1], and it has been rec-
mmended as a ﬁrst-line drug in the CPR algorithm
roposed by the American Heart Association. The
se of intravenous amiodarone was ﬁnally permit-
ed in Japan from September 2007. Amiodarone
s classiﬁed as a K+-channel blocker similar to
ifekalant hydrochloride; however, the properties
f these agents differ considerably. Amiodarone is
multiple-channel inhibitor [2], whereas nifekalant
electively blocks IKr channels [3]. Dose adjustment
f amiodarone is typically not required in patients
ith chronic kidney disease because it undergoes
iliary excretion after being metabolized in the
iver [4,5]. We encountered the case of a chronic
ialysis patient who was administered intravenous
miodarone for treating nonsustained VT (NSVT)
fter successful CPR. We investigated the relation
etween antiarrhythmic effect and the depressive
ffects of intravenous amiodarone on depolariza-
ion and repolarization by performing longitudinal
nalysis of ventricular late potentials (LPs) by using
igh-resolution Holter electrocardiogram (ECG) and
y analyzing the QT prolongation effect on a 12-
ead ECG.
ase report
n October 2007, a 63-year-old male chronic
emodialysis patient with diabetic nephropathy
height, 175 cm; weight, 75 kg) collapsed in a
rain. Loss of consciousness and absence of breath
as identiﬁed by the passengers; however, CPR
as not performed by any of the bystanders.
he emergency services personnel performed an
CG; the monitor showed asystole that evolved
nto VF by the repetitive cardiac massage. How-
ver, following cardioversion (200 J), it reverted
o asystole. The patient was transferred to our
mergency center by ambulance, and tracheal intu-
ation and epinephrine infusion were performed.
pontaneous heartbeat recovered after adminis-
ering an infusion containing 3mg of epinephrine
nd atropine each. His vital signs stabilized as fol-
ows: blood pressure; 210/120mmHg; respiratory
ate, 15/min; pulse rate, 122/min; and con-
ciousness level, Glasgow Coma Scale 1-Trachia-4.
aboratory examination demonstrated renal dys-
unction, anemia, and hyperkalemia; the values
t
f
(
c
a461
ere as follows: hemoglobin, 10.3 g/dl; creati-
ine, 10.2mg/dl; blood urea nitrogen, 68mg/dl;
, 6.2mEq/L. The 12-lead ECG showed atrial ﬁbril-
ation tachycardia with widespread ST depression,
owever soon it was converted to sinus rhythm;
chocardiography revealed normal contraction and
concentric hypertrophy. Subsequently, NSVT
120—140 bpm) appeared with hemodynamic sta-
ility, and intravenous amiodarone was initiated
hrough a central venous line with the conventional
oading dose (125mg/10min i.v.). Intermittent
emodialysis was performed every day, and the
lood concentration was analyzed by the high per-
ormance liquid chromatography (HPLC) method.
T intervals were measured in lead V2 and V5,
nd revised to QTc intervals according to Bazett
ormula, and the difference between leads V2
nd V5 which was assessed as QT-dispersion (QTd)
or spatial inhomogeneity in the myocardium. The
nterval from the peak of a T wave to the end
f a T wave (Tp-e) was calculated as the intra-
ural repolarization dispersion, and the revised
alue of Tp-e (Tcp-e) was used as the index of
he transmural dispersion for a refractory period.
o study the depressive effect on NSVT and depo-
arization, a high-resolution Holter ECG obtained
ver 30 consecutive hours (2.5V, 1000Hz; Ela
edical Co. Ltd., Paris, France) was used for
valuating the ﬂuctuations induced in LPs by the
a+-channel blocking action of the drug. The ﬁl-
ered QRS-duration (FQRS-D), the duration of the
ow-amplitude signal after the voltage decreased
o less than 40V (LAS40V), and the root-mean-
quare voltage of the signals in the last 40ms
RMS40 ms) were used as the three LP parameters.
P was analyzed every 20min, and LP is diagnosed
s positive when any two parameters showed an
bnormal value: FQRS-D >110ms, LAS40 V >32ms,
r RMS40 ms <25ms. The coefﬁcient of variance
CV) of LP was calculated by dividing the standard
eviation of LP ﬂuctuation with the mean value
CV = SD/mean).
QT prolongation was recognized at 5 h after the
nitiation, however, the QTc interval was observed
o be excessively prolonged to 582—606ms at 10 h,
nd the dose of intravenous amiodarone was there-
ore reduced (Fig. 1). Because the QTc interval
as further prolonged to 684—716ms, amiodarone
dministration was ﬁnally stopped at 24 h. QT
rolongation persisted for a further 48 h (QTc
18—661ms). However, NSVT recurred after the
ermination of amiodarone administration; there-
ore, oral amiodarone (200mg) and carvedilol
1.25mg) were administered on Day 4, with the
are of the QTc interval. QTc-d was 45ms before
miodarone administration (Fig. 1 ), and it
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Figure 1 Longitudinal time course in the QTc interval, QTc-dispersion (QTc-d), and the peak of a T wave to the end
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Dof a T wave (Tcp-e). Clinical course of QTc interval in 12-
was assessed as QTd. QTc changes are shown in leads V2
Tcp-e in leads V2 and V5 are shown in the lower table. A
decreased to 24ms at 10 h after initiating amio-
darone (Fig. 1 ). However, it increased to 31ms
again on severe QT prolongation (QTc, 684—716ms)
(Fig. 1 ), and ﬁnally increased to a maximum
value of 68ms at 12 h after discontinuing amio-
darone. It then improved gradually −43ms on Day
4 (Fig. 1 ) and 0ms on Day 7 (Fig. 1 ). Tpec in
V5 lead was 211ms before amiodarone administra-
tion; it increased to 230ms at 10 h after initiating
amiodarone, and then to 235ms after discontinuing
amiodarone; it improved to 107ms on Day 7.
NSVT was completely suppressed within 3 h
after initiating amiodarone, and furthermore, ven-
tricular premature contraction (VPC) was also
signiﬁcantly inhibited within 7 h (Fig. 2). However
VPC was obviously increased as soon as stopping
amiodarone. The LPs results of Holter analysis
showed that FQRS-D and LAS40 V were increased,
and RMS40 ms were decreased at 5 h after the
initiation of amiodarone administration, and as
a result the LPs worsened (positive conversion).
After the termination of amiodarone administra-
tion, the FQRS-D and LAS40 V decreased, RMS40
ms increased, and therefore the LPs improved (neg-
ative). With regard to the analysis of LPs-CV at the
point of LP-positive, QRS-D was 0.03ms, LAS40 V
was 0.14ms, and RMS40 ms was 0.2ms. However,
with regard to LPs-CV at the point of LP-negative,
W
o
d
iECG and the difference between leads V2 and V5 which
ite diamond) and V5 (black diamond). The intervals of
.i.v., intravenous amiodarone.
RS-D was 0.04ms, LAS40 V was 0.21ms, and
MS40 ms was 0.27ms. This implies that the LP
uctuations were inhibited effectively during amio-
arone administration.
The blood concentration reached 2.9g/ml
effective range, 1.2—2.0g/ml) within 10min
fter the initiation of amiodarone, but it immedi-
tely decreased to a concentration that was less
han the effective level after the amiodarone dose
as reduced; it almost disappeared from the blood
fter amiodarone was discontinued (Fig. 3). On
he other hand, the blood concentration of the
esethylamiodarone (DEA) — which is amiodarone’s
etabolite — was less than the measurement sensi-
ivity (50 ng/ml), and was not detected until Day 5,
nd then increased to 80—150 ng after initiating of
ral amiodarone, but less than the effective level.
emodialysis was performed on all days, and the
erum K+ level was maintained in the normal range,
.e. approximately 4mEq, on all days except Day 1.
iscussione can conclude that the onset and disappearance
f the VPC-inhibiting effect corresponded with the
epressive effect on depolarization but not with the
ncrease in the prolonged repolarization effect and
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Figure 2 The recordings of an arrhythmic event and the ﬂuctuations of late potentials (LPs) by using the high-
resolution Holter ECG. The frequency of a ventricular premature contraction (VPC) is shown in the upper panel. The
number of VPC events calculated every 1 h. Three LP parameters are shown by the dotted line as the ﬂuctuations in
FQRS-D, LAS40 V, and RMS40 ms. The positive values for FQRS-D, LAS40 V, and RMS40 ms were ≥111, ≥33ms, and
≤24V, respectively, as indicated by the graduated arrows in each ﬁgure. AMD D.i.v., intravenous amiodarone.
Figure 3 Longitudinal time course in the blood concentration of intravenous amiodarone and desethylamiodarone,
and the serum K+ value. The blood concentrations of amiodarone (AMD) and desethylamiodarone (DEA) are shown in
the upper and middle panels, respectively. The serum K+ value was indicated by the dotted line in the lower panel,
with the black arrows indicating the performance of intermittent hemodialysis (HD).
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blood concentration, at least in the present case.
Even if the QT interval is sufﬁciently prolonged,
Na+-channel blocking action is required for amio-
darone to induce the antiarrhythmic effect.
Amiodarone induces multiple antiarrhythmic
effects via blocking of Na+, Ca2+, and IKr channels,
and  receptors. In this patient, the QT-prolonging
effect of amiodarone appeared the fastest and con-
tinued for more than 48 h; however, the IKr-blocking
action was not sufﬁcient for inhibition of VPC. The
bradycardiac and blood pressure-reducing effects
via Ca2+-channel and  receptor blocking could
not be evaluated because of the use of a seda-
tive and catecholamine to stabilize the vital signs.
The different backgrounds of the patients with car-
diopulmonary arrest (CPA) inﬂuence the contents
of CPR. Therefore, it is difﬁcult to understand the
multiple pharmacological actions of amiodarone in
CPR.
The possible explanations for excessive QT
prolongation in this case might be: (1) the nor-
malization of serum K+ levels induced IKr-blocking
action; (2) the reverse frequency-dependent effect
of the IKr-blocking action was involved in the 
receptor-blocking action of amiodarone itself; (3)
the reduction in catecholamine augmented the
effect of the IKr-blocking action and (4) the severe
hypoxia and lactic acidosis attenuated the capacity
for repolarization reserve by decreasing the number
of K+ channels.
In addition, the excessive QT prolongation
caused a signiﬁcant increase in QTc-d and Tcp-e,
and more time was required for its normaliza-
tion even after discontinuing amiodarone. Aiba
et al. have examined QTc and Tcp-e intervals by
87-electrode mapping in 50 patients before and
after treatment with oral amiodarone, and they
have suggested that signiﬁcant QT prolongation and
transmural dispersion could be predictive factors
for VT recurrence after the use of oral amiodarone
[6]. According to their report, the V5 Tcp-e inter-
val before oral amiodarone intake was 85± 13ms on
an average; however, in our case, Tcp-e had already
increased to 211ms before intravenous amiodarone
administration. Tcp-e prolongation may be an index
for the prediction of vulnerability to excessive QT
prolongation.
The blood concentration of amiodarone showed
that different ﬂuctuations correspond to the antiar-
rhythmic effect. Because, the blood concentration
only once reached the effective level just after
the administration, but soon decreased, and DEA
was below measurable levels during amiodarone
infusion in this case. The tissue transfer ability
of intravenous amiodarone is highly superior [7];
for example, after intravenous amiodarone injec-K. Yoshioka et al.
ion, its concentration in the myocardium rapidly
chieves a level that is ﬁve times its correspond-
ng plasma concentration within 5min [8]. As for
ral amiodarone, the transfer ratios of organs such
s the heart, liver, and lungs vary considerably in
ndividuals. Oral amiodarone also shows the high-
st accumulation in adipose tissue because of its
at solubility [9]. On the basis of these reports, it is
ot entirely clear whether the blood concentration
f amiodarone reﬂects the antiarrhythmic effect.
In the analysis of depolarization time, it was
evealed that amiodarone induced the antiar-
hythmic effect by stabilization of LPs. The LP
arameters seemed to worsen and became posi-
ive, but the LP ﬂuctuations became small, perhaps
ecause amiodarone resulted in uniform conduc-
ion delay and homogeneous electrical stability in
he ischemic heart. Kobayashi et al. reported that
he FQRS-D increased after the administration of
ral amiodarone (400mg/day), but VT recurrence
as suppressed [10]. Borbola et al. evaluated 14 VT
atients on oral amiodarone (400—1400mg/day);
of the 4 LP-negative patients with inducible VT
eveloped LPs while on amiodarone therapy [11].
t is assumed that LP values and ﬂuctuations reﬂect
he Ito channel- and L-type Ca2+-channel blocking
f oral amiodarone, besides its blocking actions on
a+, IKr, and IKs channels, and  receptors. How-
ver, with regard to intravenous amiodarone, it is
ssumed that the LP values and ﬂuctuations reﬂect
he Na+-channel blocking action. Further examina-
ion will be necessary to elucidate the mechanisms
f the improvement of the electrical instability
nderlying the LP aggravations by amiodarone.
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